|
|
||
|
|
||
| General information | Expression | Regulation | Mutation | Interaction |
|
Basic Information |
|
|---|---|
Gene ID | 1540 |
Name | CYLD |
Synonym | BRSS|CDMT|CYLD1|CYLDI|EAC|MFT|MFT1|SBS|TEM|USPL2;cylindromatosis (turban tumor syndrome);CYLD;cylindromatosis (turban tumor syndrome) |
Definition | deubiquitinating enzyme CYLD|probable ubiquitin carboxyl-terminal hydrolase CYLD|ubiquitin carboxyl-terminal hydrolase CYLD|ubiquitin specific peptidase like 2|ubiquitin thioesterase CYLD|ubiquitin thiolesterase CYLD|ubiquitin-specific-processing protease |
Position | 16q12.1 |
Gene Type | protein-coding |
Source | Count: 3; Pubmed_search,Generif,UniProt |
Literature support | Count: 19 PubMed records as below. |
|
Evidence Status |
Description |
reviewed | Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. |
reviewed | Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. |
reviewed | tumor suppressor cylindromatosis acts as a negative regulator for Streptococcus pneumoniae-induced NFAT signaling. |
reviewed | tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. |
reviewed | Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. |
reviewed | tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. |
reviewed | "Recurrent inactivation of CYLD occurs through diverse mechanisms in several forms of cancer, unequivocally confirming its tumor suppressor function. It negatively regulates several signaling pathway,including NF-kappaB. Review." |
reviewed | Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. |
reviewed | tumor suppressor cylindromatosis: expressed in IgA nephropathy and negatively associated with renal tubulo-interstitial lesion. |
reviewed | Results suggest that IKKepsilon and CYLD function as an oncogene-tumor suppressor network that participates in tumorigenesis. |
| More detail of all 19 literatures about CYLD | |
|
Pathways and Diseases |
|
Pathway | Canonical NF-kappaB pathway;PID Curated;200026 |
Pathway | TNF receptor signaling pathway;PID Curated;200086 |
Pathway | RIG-I-like receptor signaling pathway;KEGG PATHWAY;hsa04622 |
Disease | Multiple familial trichoepithelioma and familial cylindromatosis;GAD |
Disease | Infectious lung disease;FunDO |
Disease | Spiegler-Brooke syndrome;OMIM |
Disease | Multiple myeloma;FunDO |
Disease | CANCER;GAD |
Disease | Cylindromatosis, familial;OMIM |
Disease | Trichoepithelioma, multiple familial, 1;OMIM |
Disease | Hodgkin's disease;FunDO |
Disease | Liver cancer;FunDO |
Disease | Adenoid cystic cancer;FunDO |
Disease | Brooke-Spiegler syndrome;OMIM |
|
External Links |
|
Links to Entrez Gene | 1540 |
Links to all GeneRIF Items | 1540 |
Links to iHOP | 1540 |
|
Sequence Information |
|
Nucleotide Sequence |
>1540 : length: 2862 atgagttcaggcttatggagccaagaaaaagtcacttcaccctactgggaagagcggatt ttttacttgcttcttcaagaatgcagcgttacagacaaacaaacacaaaagctccttaaa gtaccgaagggaagtataggacagtatattcaagatcgttctgtggggcattcaaggatt ccttctgcaaaaggcaagaaaaatcagattggattaaaaattctagagcaacctcatgca gttctctttgttgatgaaaaggatgttgtagagataaatgaaaagttcacagagttactt ttggcaattaccaattgtgaggagaggttcagcctgtttaaaaacagaaacagactaagt aaaggcctccaaatagacgtgggctgtcctgtgaaagtacagctgagatctggggaagaa aaatttcctggagttgtacgcttcagaggacccctgttagcagagaggacagtctccgga atattctttggagttgaattgctggaagaaggtcgtggtcaaggtttcactgacggggtg taccaagggaaacagctttttcagtgtgatgaagattgtggcgtgtttgttgcattggac aagctagaactcatagaagatgatgacactgcattggaaagtgattacgcaggtcctggg gacacaatgcaggtcgaacttcctcctttggaaataaactccagagtttctttgaaggtt ggagaaacaatagaatctggaacagttatattctgtgatgttttgccaggaaaagaaagc ttaggatattttgttggtgtggacatggataaccctattggcaactgggatggaagattt gatggagtgcagctttgtagttttgcgtgtgttgaaagtacaattctattgcacatcaat gatatcatcccagagagtgtgacgcaggaaaggaggcctcccaaacttgcctttatgtca agaggtgttggggacaaaggttcatccagtcataataaaccaaaggctacaggatctacc tcagaccctggaaatagaaacagatctgaattattttataccttaaatgggtcttctgtt gactcacaaccacaatccaaatcaaaaaatacatggtacattgatgaagttgcagaagac cctgcaaaatctcttacagagatatctacagactttgaccgttcttcaccaccactccag cctcctcctgtgaactcactgaccaccgagaacagattccactctttaccattcagtctc accaagatgcccaataccaatggaagtattggccacagtccactttctctgtcagcccag tctgtaatggaagagctaaacactgcacccgtccaagagagtccacccttggccatgcct cctgggaactcacatggtctagaagtgggctcattggctgaagttaaggagaaccctcct ttctatggggtaatccgttggatcggtcagccaccaggactgaatgaagtgctcgctgga ctggaactggaagatgagtgtgcaggctgtacggatggaaccttcagaggcactcggtat ttcacctgtgccctgaagaaggcgctgtttgtgaaactgaagagctgcaggcctgactct aggtttgcatcattgcagccggtttccaatcagattgagcgctgtaactctttagcattt ggaggctacttaagtgaagtagtagaagaaaatactccaccaaaaatggaaaaagaaggc ttggagataatgattgggaagaagaaaggcatccagggtcattacaattcttgttactta gactcaaccttattctgcttatttgcttttagttctgttctggacactgtgttacttaga cccaaagaaaagaacgatgtagaatattatagtgaaacccaagagctactgaggacagaa attgttaatcctctgagaatatatggatatgtgtgtgccacaaaaattatgaaactgagg aaaatacttgaaaaggtggaggctgcatcaggatttacctctgaagaaaaagatcctgag gaattcttgaatattctgtttcatcatattttaagggtagaacctttgctaaaaataaga tcagcaggtcaaaaggtacaagattgttacttctatcaaatttttatggaaaaaaatgag aaagttggcgttcccacaattcagcagttgttagaatggtcttttatcaacagtaacctg aaatttgcagaggcaccatcatgtctgattattcagatgcctcgatttggaaaagacttt aaactatttaaaaaaatttttccttctctggaattaaatataacagatttacttgaagac actcccagacagtgccggatatgtggagggcttgcaatgtatgagtgtagagaatgctac gacgatccggacatctcagctggaaaaatcaagcagttttgtaaaacctgcaacactcaa gtccaccttcatccgaagaggctgaatcataaatataacccagtgtcacttcccaaagac ttacccgactgggactggagacacggctgcatcccttgccagaatatggagttatttgct gttctctgcatagaaacaagccactatgttgcttttgtgaagtatgggaaggacgattct gcctggctcttctttgacagcatggccgatcgggatggtggtcagaatggcttcaacatt cctcaagtcaccccatgcccagaagtaggagagtacttgaagatgtctctggaagacctg cattccttggactccaggagaatccaaggctgtgcacgaagactgctttgtgatgcatat atgtgcatgtaccagagtccaacaatgagtttgtacaaataa |
Protein Sequence |
>1540 : length: 953 MSSGLWSQEKVTSPYWEERIFYLLLQECSVTDKQTQKLLKVPKGSIGQYIQDRSVGHSRI PSAKGKKNQIGLKILEQPHAVLFVDEKDVVEINEKFTELLLAITNCEERFSLFKNRNRLS KGLQIDVGCPVKVQLRSGEEKFPGVVRFRGPLLAERTVSGIFFGVELLEEGRGQGFTDGV YQGKQLFQCDEDCGVFVALDKLELIEDDDTALESDYAGPGDTMQVELPPLEINSRVSLKV GETIESGTVIFCDVLPGKESLGYFVGVDMDNPIGNWDGRFDGVQLCSFACVESTILLHIN DIIPESVTQERRPPKLAFMSRGVGDKGSSSHNKPKATGSTSDPGNRNRSELFYTLNGSSV DSQPQSKSKNTWYIDEVAEDPAKSLTEISTDFDRSSPPLQPPPVNSLTTENRFHSLPFSL TKMPNTNGSIGHSPLSLSAQSVMEELNTAPVQESPPLAMPPGNSHGLEVGSLAEVKENPP FYGVIRWIGQPPGLNEVLAGLELEDECAGCTDGTFRGTRYFTCALKKALFVKLKSCRPDS RFASLQPVSNQIERCNSLAFGGYLSEVVEENTPPKMEKEGLEIMIGKKKGIQGHYNSCYL DSTLFCLFAFSSVLDTVLLRPKEKNDVEYYSETQELLRTEIVNPLRIYGYVCATKIMKLR KILEKVEAASGFTSEEKDPEEFLNILFHHILRVEPLLKIRSAGQKVQDCYFYQIFMEKNE KVGVPTIQQLLEWSFINSNLKFAEAPSCLIIQMPRFGKDFKLFKKIFPSLELNITDLLED TPRQCRICGGLAMYECRECYDDPDISAGKIKQFCKTCNTQVHLHPKRLNHKYNPVSLPKD LPDWDWRHGCIPCQNMELFAVLCIETSHYVAFVKYGKDDSAWLFFDSMADRDGGQNGFNI PQVTPCPEVGEYLKMSLEDLHSLDSRRIQGCARRLLCDAYMCMYQSPTMSLYK |